{"altmetric_id":9633001,"counts":{"readers":{"mendeley":6,"citeulike":0,"connotea":0},"total":{"posts_count":2},"wikipedia":{"unique_users_count":1,"unique_users":["en:13033422"],"posts_count":2}},"citation":{"altmetric_jid":"4f6fa5e93cf058f610005a98","authors":["Roger Lee Mendoza"],"doi":"10.1007\/s10389-013-0561-z","endpage":"218","first_seen_on":"2016-07-12T18:14:48+00:00","issns":["1613-2238"],"issue":"3","journal":"Journal of Public Health","last_mentioned_on":1468347279,"links":["http:\/\/link.springer.com\/article\/10.1007%2Fs10389-013-0561-z","http:\/\/dx.doi.org\/10.1007%2Fs10389-013-0561-z"],"pdf_url":"http:\/\/link.springer.com\/content\/pdf\/10.1007%2Fs10389-013-0561-z.pdf","pubdate":"2013-05-02T00:00:00+00:00","publisher":"Springer Berlin Heidelberg","publisher_subjects":[{"name":"Public Health And Health Services","scheme":"era"},{"name":"Epidemiology","scheme":"springer"},{"name":"Health Promotion and Disease Prevention","scheme":"springer"},{"name":"Medicine & Public Health","scheme":"springer"},{"name":"Public Health","scheme":"springer"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"211","title":"Pharmacoeconomics and clinical trials in multiple sclerosis: baseline data from the European Union","type":"article","volume":"22","mendeley_url":"http:\/\/www.mendeley.com\/research\/pharmacoeconomics-clinical-trials-multiple-sclerosis-baseline-data-european-union-1"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":8069135,"mean":6.8476973499224,"rank":2028618,"this_scored_higher_than_pct":61,"this_scored_higher_than":4928729,"rank_type":"exact","sample_size":8069135,"percentile":61},"similar_age_3m":{"total_number_of_other_articles":258753,"mean":11.687855444595,"rank":83448,"this_scored_higher_than_pct":66,"this_scored_higher_than":171448,"rank_type":"exact","sample_size":258753,"percentile":66},"this_journal":{"total_number_of_other_articles":1238,"mean":9.0732223120453,"rank":536,"this_scored_higher_than_pct":44,"this_scored_higher_than":546,"rank_type":"exact","sample_size":1238,"percentile":44},"similar_age_this_journal_3m":{"total_number_of_other_articles":31,"mean":5.225,"rank":14,"this_scored_higher_than_pct":54,"this_scored_higher_than":17,"rank_type":"exact","sample_size":31,"percentile":54}}},"demographics":{"users":{"mendeley":{"by_status":{"Student  > Doctoral Student":1,"Student  > Postgraduate":2,"Student  > Master":3},"by_discipline":{"Medicine and Dentistry":4,"Agricultural and Biological Sciences":2}}}},"posts":{"wikipedia":[{"title":"Multiple sclerosis research","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=729511485#altmetric_citation_f614e6dd-fb8f-4b70-9f54-1792a248d15a","license":"public","citation_ids":[9633001,9633001],"posted_on":"2016-07-12T18:14:39+00:00","summary":"Treatments under investigation for multiple sclerosis may improve function, curtail attacks, or limit the progression of the underlying disease.","page_url":"http:\/\/en.wikipedia.org\/?curid=13033422","wiki_lang":"en","author":{"name":"Rjwilmsi","url":"http:\/\/en.wikipedia.org\/wiki\/User:Rjwilmsi"}},{"title":"Multiple sclerosis research","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=729511485#altmetric_citation_93954556-5e46-4f09-b8af-f2696fc65f7f","license":"public","citation_ids":[9633001,9633001],"posted_on":"2016-07-12T18:14:39+00:00","summary":"Treatments under investigation for multiple sclerosis may improve function, curtail attacks, or limit the progression of the underlying disease.","page_url":"http:\/\/en.wikipedia.org\/?curid=13033422","wiki_lang":"en","author":{"name":"Rjwilmsi","url":"http:\/\/en.wikipedia.org\/wiki\/User:Rjwilmsi"}}]}}